AT&T Inc. <T.N>: MoffettNathanson cuts target price to $23 from $24
T•Related News
Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results at the International Congress of the Transplantation Society
ELDN•
GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma
GSK•
CorVel launches CareMC Accelerator integration for Guidewire ClaimCenter on Guidewire Marketplace
CRVL•
Venu partners with Hunt Sports, Peak Curated to develop mixed-use district at Toyota Stadium in Frisco, Texas
VENU•
Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In IgG4-Related Disease At The IgG4WARD! 6th International Symposium On IgG4-Related Disease And ACR Convergence 2026
ZBIO•